Colon Cancer Survival Varies by Insurance Type

Share this content:
Colon Cancer Survival Varies by Insurance Type
Colon Cancer Survival Varies by Insurance Type

FRIDAY, April 20, 2018 (HealthDay News) -- Compared to patients with private insurance, colon cancer survival is lower for patients with no insurance or with Medicaid, according to a study published in the May issue of Diseases of the Colon & Rectum.

Dianne Pulte, M.D., from the German Cancer Research Center in Heidelberg, and colleagues examined survival for patients with colon cancer by insurance type (Medicaid, uninsured, or other insurance) using a sample derived from the Surveillance, Epidemiology, and End Results 18 database.

The researchers found that of the 55,432 patients, 13.7 percent had Medicaid, 7.5 percent no insurance, and 78.8 percent other insurance. Compared to patients with other insurance, those with Medicaid or without insurance were more likely to have metastatic disease. Survival was lowest for patients with Medicaid, with three-year survival estimates of 57.0 percent for Medicaid, 61.2 percent for uninsured, and 75.6 percent for other insurance. Even after adjustment for stage, especially for later-stage disease, significant disparities persisted, but the discrepancy decreased when only patients with stage I to II disease who had definitive surgery and resection of ≥12 lymph nodes were included in the analysis.

"Colon cancer survival is lower for patients with no insurance or with Medicaid than for those with private insurance," the authors write. "Differences in rates of definitive surgery and adequate lymph node dissection explain some of this disparity."

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »